Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16577975 | 0.89 | GAA (0.40) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL20902084 | 0.89 | GAA (0.40) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL20902091 | 0.89 | GAA (0.40) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL14233174 | 0.89 | GAA (0.40) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL20902098 | 0.89 | GAA (0.40) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL23790829 | 0.86 | GAA (0.38) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL4267818 | 0.85 | GAA (0.48) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL21871392 | 0.82 | MAOB (0.44) | ALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL14238192 | 0.81 | GAA (0.43) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL14234032 | 0.81 | GAA (0.43) | GAAALDH1A1CYP1A2CYP2C9RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | GAA 4189/4885ALDH1A1 3508/4885CYP1A2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.